Iconovo AB today announced that the ICOres™ budesonide/formoterol project (generic Symbicort®) will be transferred to the global partner Amneal Ireland Limited from CBC Corporation (India) Private Limited. Amneal Ireland Limited will take over all existing obligations of CBC under the current agreement. The project will continue according to plan.

The ICOres budesonide/formoterol product has already been tested in a pilot clinical pharmacokinetic study in healthy volunteers (communicated in July 2019). The results showed excellent correspondence with regards to budesonide and slightly higher values with regards to formoterol for ICOres. The results are currently being used to finalize the remaining development work, to fully match ICOres to the original product.

The value of the global budesonide/formoterol combination market is about $2.5 billion annually. Iconovo is developing its multi-dose reservoir inhaler ICOres™ and a dry powder formulation to treat asthma and chronic obstructive pulmonary disease (COPD).

”Iconovo welcomes Amneal as a development partner for our Symbicort® project. As we are closing into making larger investments in the project, we feel that Amneal is best positioned to support the project with the required resources and give certainty to the development track. It is a key priority for Iconovo to reach the patients in a timely manner to benefit from the turnover related royalty payments to the company. We look forward to working with Amneal on this exciting project.” says Johan Wäborg, CEO for Iconovo.

Amneal Co-Chief Executive Officer Chintu Patel said: “Developing a range of inhalation products remains an important element of Amneal’s portfolio strategy. Amneal expects that combining Iconovo’s extensive experience in inhalation development with Amneal’s capability to bring complex generic medicines to market will set this partnership apart.”

About ICOres
ICOres is a flexible multi-dose dry powder inhaler with feedback features developed by Iconovo. It features two separate reservoirs which allows for simultaneous inhalation of two different formulations that makes it suitable for combination products. Its intuitive handling, exact dose counting, and clear inhalation feedback helps the patient staying compliant with the treatment. ICOres is ready for commercial manufacturing making it the best alternative for pharmaceutical companies seeking a reservoir inhaler.

About Amneal
Amneal Ireland Limited is a fully owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) headquartered in Bridgewater, NJ., focused on the development, manufacturing and distribution of inhalation products. Amneal Pharmaceuticals, Inc., is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.
For more information, visit https://www.amneal.com.